MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3% – Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s stock price was down 7.3% on Monday . The company traded as low as $17.52 and last traded at $17.1480. Approximately 815,548 shares were traded during trading, a decline of 88% from the average daily volume of 6,866,944 shares. The stock had previously closed at $18.49.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MLTX shares. Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research report on Tuesday, September 30th. UBS Group set a $24.00 price target on MoonLake Immunotherapeutics in a report on Friday. Oppenheimer restated an “outperform” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, November 6th. Jefferies Financial Group cut MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 target price on the stock. in a research note on Monday, September 29th. Finally, Guggenheim reduced their price target on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 30th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Hold” and a consensus target price of $25.54.

MoonLake Immunotherapeutics Stock Down 2.2%

The company has a market cap of $1.16 billion, a price-to-earnings ratio of -5.45 and a beta of 1.21. The stock has a 50-day simple moving average of $13.18 and a 200-day simple moving average of $31.35. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter in the prior year, the business earned ($0.56) earnings per share. As a group, analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 402,908 shares of company stock worth $5,987,162 over the last 90 days. 12.05% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in shares of MoonLake Immunotherapeutics during the 2nd quarter valued at about $74,000. FNY Investment Advisers LLC acquired a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Bank of America Corp DE boosted its holdings in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after buying an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares during the last quarter. Finally, Covestor Ltd acquired a new position in MoonLake Immunotherapeutics in the third quarter worth approximately $46,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.